Aetna Sues Takeda Over Alleged Anticompetitive Tactics in Amitiza Generic Delay

A legal dispute has emerged as Aetna has filed a lawsuit in Massachusetts against Takeda Pharmaceuticals, alleging that the company engaged in anticompetitive practices to maintain its profits. According to the claims, Takeda entered into an agreement with Par Pharmaceutical to intentionally keep a generic version of its anticonstipation drug, Amitiza, off the market. This arrangement reportedly took place following the expiration of the drug’s compound patent. As a result, Aetna asserts that it was forced to pay inflated prices, costing millions of dollars in overcharges for the branded version of the medication. Details surrounding these allegations are outlined in a report by Law360.